Pt # | Grade | OR | KPS | # of cycles of pembro | MGMT Status | IDH Status | 1p/19q | ML | Steroids at initiation | Steroid dose at initiation (in prednisone equivalence) | # of cycles with steroids | ConBev | Prev Bev | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

0 | <20 | ≥20 | |||||||||||||

1 | III | PR | 90 | 4 | unmethylated | WT | N/A | 6 | N | X | 2 | Y | Y | ||

2 | IV | PR | 80 | 4 | unmethylated | N/A | N/A | 6 | Y | X | 1 | Y | N | ||

3 | III | SD | 90 | 14 | methylated | WT | intact | 6 | N | X | 0 | N | N | ||

4 | III | SD | 70 | 10 | unmethylated | MUT | N/A | 3 | Y | X | 1 | Y | Y | ||

5 | IV | SD | 90 | 14 | unmethylated | WT | N/A | 12 | N | X | 5 | Y | Y | ||

6 | IV | SD | 100 | 4 | methylated | N/A | N/A | 13 | N | X | 0 | N | Y | ||

7 | IV | SD | 100 | 1 | N/A | WT | N/A | N/A | Y | X | 1 | Y | Y | ||

8 | III | PD | 90 | 6 | N/A | MUT | co-del | 5 | Y | X | 1 | N | N | ||

9 | III | PD | 60 | 5 | N/A | MUT | co-del | 58 | Y | X | 0 | Y | Y | ||

10 | III | PD | 60 | 3 | unmethylated | MUT | N/A | 7 | N | X | 2 | N | N | ||

11 | III | PD | 70 | 3 | unmethylated | WT | N/A | 5 | Y | X | 3 | Y | Y | ||

12 | III | PD | 90 | 2 | unmethylated | WT | intact | 15 | Y | X | 2 | Y | N | ||

13 | III | PD | 90 | 2 | unmethylated | MUT | N/A | 7 | Y | X | 2 | Y | Y | ||

14 | III | PD | N/A | 1 | methylated | MUT | N/A | 5 | N | X | 0 | N | Y | ||

15 | IV | PD | 90 | 5 | methylated | MUT | N/A | 11 | Y | X | 2 | N | N | ||

16 | IV | PD | 60 | 5 | unmethylated | WT | intact | 10 | Y | X | 2 | Y | Y | ||

17 | IV | PD | 50 | 4 | N/A | N/A | N/A | N/A | N | X | 0 | Y | Y | ||

18 | IV | PD | 90 | 3 | N/A | MUT | N/A | 9 | Y | X | 3 | Y | Y | ||

19 | IV | PD | 90 | 3 | unmethylated | N/A | N/A | 4 | Y | X | 1 | Y | Y | ||

20 | IV | PD | 90 | 3 | N/A | N/A | N/A | N/A | N | X | 1 | Y | Y | ||

21 | IV | PD | 70 | 2 | unmethylated | WT | N/A | 13 | Y | X | 2 | Y | Y | ||

22 | IV | PD | 80 | 2 | unmethylated | MUT | N/A | 5 | N | X | 0 | Y | Y | ||

23 | IV | PD | 80 | 2 | N/A | WT | N/A | N/A | N | X | 1 | Y | Y | ||

24 | N/A | PD | 70 | 2 | N/A | N/A | N/A | N/A | N | X | 1 | Y | Y | ||

25 | IV | N/A | 60 | 1 | N/A | MUT | intact | 19 | Y | X | 1 | Y | Y |

Abbreviations: Pt: Patient; OR: Objective response; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; KPS: Karnofsky performance score; Pembro: pembrolizumab; N/A: not applicable or unknown; MGMT methylated: methylated; MGMT unmethylated: unmethylated; IDH mutant: MUT; IDH wild type: WT; 1p19q intact: intact; 1p19q codeleted: Co-del; ML: mutational load by MSK impact; Y: yes; N: no; X: indicates steroid dose at initiation; Con Bev: Concomitant bevacizumab; Prev Bev: previously progressed on bevacizumab treatment